Opus Genetics (IRD) Capital Expenditures (2010 - 2019)

Opus Genetics (IRD) posted quarterly Capital Expenditures of $5617.0 for Q4 2019, down 9.43% quarter-over-quarter from $6202.0 in Q2 2019.

Opus Genetics (IRD) Capital Expenditures (2010 - 2019) Analysis & Trends

Opus Genetics (IRD) has reported Capital Expenditures for 9 consecutive years, with $5617.0 the latest figure, recorded in Q4 2019.

In Q4 2019, Capital Expenditures changed N/A year-over-year to $5617.0; the TTM figure through Dec 2019 stood at $25000.0 (down 36.26% YoY), while the FY2019 annual figure was $25000.0, down 36.26% from the prior year.
Capital Expenditures fell to $5617.0 in Q4 2019 per IRD's latest filing, from $6202.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $53799.0 in Q4 2017 and bottomed at $403.0 in Q4 2016.
Historically, Capital Expenditures has averaged $11686.7 across 5 years, with a median of $5106.5 in 2016.
Annual changes were most pronounced in 2016 — Capital Expenditures plunged 98.13% — and 2017, when it surged 13249.63%.
Opus Genetics' Capital Expenditures stood at $9803.0 in 2015, then slumped by 95.89% to $403.0 in 2016, then soared by 13249.63% to $53799.0 in 2017, then slumped by 33.58% to $35731.0 in 2018, then sank by 84.28% to $5617.0 in 2019.
Business Quant data shows IRD's Capital Expenditures at $5617.0 in Q4 2019, $6202.0 in Q2 2019, and $13181.0 in Q1 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	2.29 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.02 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	572,662.23
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	251.02 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	34.68 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	6.26 Mn
10	Opus Genetics	298.36 Mn	209.55 Mn	-	-

Download Data